Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin–bleomycin–vinblastine–dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long-term efficacy results of a retrospective multicentre study / Giordano, C.; Picardi, M.; Pugliese, N.; Vincenzi, A.; Avilia, S.; De Fazio, L.; Lamagna, M.; Reina, R.; Scarpa, A.; Lombardi, A.; Vigliar, E.; Troncone, G.; Mascolo, M.; Mainolfi, C.; Fonti, R.; Del Vecchio, S.; Damiano, V.; Bianco, R.; Trastulli, F.; Annunziata, M.; Salemme, A.; Carchia, M.; Pane, F.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 1365-2141. - 206:5(2025), pp. 1502-1507. [10.1111/bjh.20053]
Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin–bleomycin–vinblastine–dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long-term efficacy results of a retrospective multicentre study
Giordano C.
Primo
Formal Analysis
;Pugliese N.;Vincenzi A.;De Fazio L.;Reina R.;Vigliar E.;Mainolfi C.;Fonti R.;Del Vecchio S.;Damiano V.;Trastulli F.;Carchia M.;
2025
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
